Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures

References

• Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol. 1984;2(4 ):343–366. doi:10.1016/S0167-8140(84)80077-86097949
   PubMed Web of Science ®Google Scholar
• Alfarouk KO, Verduzco D, Rauch C, et al. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience. 2014;1(12 ):777–802. doi:10.18632/oncoscience.10925621294
   PubMedGoogle Scholar
• Raghunand N, He X, Van Sluis R, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer. 1999;80(7 ):1005–1011. doi:10.1038/sj.bjc.669045510362108
   PubMed Web of Science ®Google Scholar
• Wojtkowiak JW, Verduzco D, Schramm KJ, Gillies RJ. Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011;8(6 ):2032–2038. doi:10.1021/mp200292c21981633
   PubMedGoogle Scholar
• Faes S, Dormond O. Systemic buffers in cancer therapy: the example of sodium bicarbonate; stupid idea or wise remedy? Med Chem (Los Angeles). 2016;5(12 ):540–544. doi:10.4172/2161-0444.1000314
   Google Scholar
• Maxson ME, Grinstein S. The vacuolar-type H+-ATPase at a glance - more than a proton pump. J Cell Sci. 2014;127(23 ):4987–4993. doi:10.1242/jcs.15855025453113
   PubMed Web of Science ®Google Scholar
• Sennoune SR, Bakunts K, Martínez GM, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004;286(6 ):C1443–C1452. doi:10.1152/ajpcell.00407.200314761893
   PubMed Web of Science ®Google Scholar
• Gleize V, Boisselier B, Marie Y, Poëa-Guyon S, Sanson M, Morel N. The renal v-ATPase a4 subunit is expressed in specific subtypes of human gliomas. Glia. 2012;60(6 ):1004–1012. doi:10.1002/glia.2233222460948
   PubMed Web of Science ®Google Scholar
• Chung C, Mader CC, Schmitz JC, et al. The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Investig. 2011;91:732–743. doi:10.1038/labinvest.2011.821339745
   PubMed Web of Science ®Google Scholar
• Kulshrestha A, Ibrahim S, Pamarthy S, et al. Vacuolar ATPase isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer. Oncotarget. 2015;6(6 ). doi:10.18632/oncotarget.2902
   Google Scholar
• Lu Q, Lu S, Huang L, et al. The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer. Diagn Pathol. 2013;8:145. doi:10.1186/1746-1596-8-14523984887
   PubMed Web of Science ®Google Scholar
• Yasui N, Sun-Wada G-H, Wada Y, et al. The a3 isoform vacuolar type H+-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011;9(7 ):845–855. doi:10.1158/1541-7786.mcr-10-044921669964
   PubMed Web of Science ®Google Scholar
• Xu J, Xie R, Liu X, et al. Expression and functional role of vacuolar H+-ATPase in human hepatocellular carcinoma. Carcinogenesis. 2012;33(12 ):2432–2440. doi:10.1093/carcin/bgs27722962303
   PubMed Web of Science ®Google Scholar
• Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6 ):528–534. doi:10.1007/s11894-008-0098-419006606
   PubMedGoogle Scholar
• Tomassetti P, Campana D, Piscitelli L, et al. Treatment of Zollinger-Ellison syndrome. World J Gastroenterol. 2005;11(35 ):5423–5432. doi:10.3748/wjg.v11.i35.542316222731
   PubMed Web of Science ®Google Scholar
• Patel KJ, Lee C, Tan Q, Tannock IF. Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors. Clin Cancer Res. 2013;19(24 ):6766–6776. doi:10.1158/1078-0432.CCR-13-012824141627
   PubMed Web of Science ®Google Scholar
• Lugini L, Federici C, Borghi M, et al. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem. 2016;31(4 ):538–545. doi:10.3109/14756366.2015.104606226018420
   PubMed Web of Science ®Google Scholar
• Gawron AJ, Feinglass J, Pandolfino JE, Tan BK, Bove MJ, Shintani-Smith S. Brand name and generic proton pump inhibitor prescriptions in the United States: insights from the National Ambulatory Medical Care Survey (2006–2010). Gastroenterol Res Pract. 2015;2015:1–7. doi:10.1155/2015/689531
   Web of Science ®Google Scholar
• Hálfdánarson Ó, Pottegård A, Björnsson ES, et al. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol. 2018;11:175628481877794. doi:10.1177/1756284818777943
   Web of Science ®Google Scholar
• Zeichner SB, Terawaki H, Gogineni KA. Review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl). 2016;10:25–36. doi:10.4137/BCBCR.S3278327042088
   PubMed Web of Science ®Google Scholar
• Jiang W, Lionberger R, Yu LX. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis. 2011;3(3 ):333–344. doi:10.4155/bio.10.20421320053
   PubMed Web of Science ®Google Scholar
• Tseng H, Gage JA, Shen T, et al. A spheroid toxicity assay using magnetic 3D bioprinting and real-time mobile device-based imaging. Sci Rep. 2015;5(1 ):13987. doi:10.1038/srep1398726365200
   PubMedGoogle Scholar
• Yu M, Lee C, Wang M, Tannock IF. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Sci. 2015;106(10 ):1438–1447. doi:10.1111/cas.1275626212113
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22 ):1702–1713. doi:10.1093/jnci/djh30515547183
   PubMed Web of Science ®Google Scholar
• Kromer W, Krüger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology. 1998;56(2 ):57–70. doi:10.1159/0000281839494064
   PubMed Web of Science ®Google Scholar
• Faes S, Dormond O. Systemic buffers in cancer therapy: the example of sodium bicarbonate; stupid idea or wise remedy? Med Chem (Los Angeles). 2015;5(12 ):540–544. doi:10.4172/2161-0444.1000314
   Google Scholar
• Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70(5 ):101. doi:10.5688/aj700510117149430
   PubMed Web of Science ®Google Scholar
• Wang X, Liu C, Wang J, Fan Y, Wang Z. Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget. 2017;8(35 ):58801–58808. doi:10.18632/oncotarget.1852228938598
   PubMedGoogle Scholar
• Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J Transl Med. 2013;11(1 ):1. doi:10.1186/1479-5876-11-26823281771
   PubMedGoogle Scholar
• Beyenbach KW. The V-type H+ ATPase: molecular structure and function, physiological roles and regulation. J Exp Biol. 2006;209(4 ):577–589. doi:10.1242/jeb.0201416449553
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Khanam J, Sarkar P, Pal TK. A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics. RSC Adv. 2019;9(1 ):240–254. doi:10.1039/C8RA08924H
   PubMed Web of Science ®Google Scholar